MedPath

Sotatercept

Generic Name
Sotatercept
Brand Names
Winrevair
Drug Type
Biotech
Chemical Formula
-
CAS Number
1001080-50-7
Unique Ingredient Identifier
0QI90BTJ37
Background

Sotatercept has been used in trials studying the supportive care and treatment of Anemia, Leukemia, Solid Tumors, Bladder Cancer, and multiple myeloma, among others.

Associated Conditions
-
Associated Therapies
-

Winrevair Advanced PAH Trial Stopped Early Due to 'Overwhelming' Efficacy

Merck's PAH medication Winrevair (sotatercept) showed significant reduction in morbidity and mortality risk in advanced PAH patients, leading to early conclusion of ZENITH trial. The therapy, approved by FDA in 2024, aims to increase exercise capacity and reduce clinical worsening events, with plans to submit ZENITH data for potential indication expansion.
investing.com
·

FDA grants breakthrough designation to Merck's lung cancer therapy

Merck announced FDA Breakthrough Therapy designation for sacituzumab tirumotecan (sac-TMT) for EGFR-mutated NSCLC, based on Phase 2 study results. Merck is advancing sac-TMT's clinical development to improve cancer care, with ongoing Phase 3 studies and a first marketing authorization in China for TNBC.
pmlive.com
·

Merck shares positive phase 3 results for pulmonary arterial hypertension therapy

Merck & Co's Winrevair (sotatercept-csrk) met primary endpoint in phase 3 ZENITH study, showing significant reduction in PAH morbidity/mortality risk. Independent committee recommends trial stop and open-label extension.
finance.yahoo.com
·

Pharma Stock Roundup: RHHBY to Buy PSTX, MRK, AZN See Pipeline Success

Roche to acquire Poseida Therapeutics for $1 billion. Merck, AstraZeneca, and Novartis see success in new drug studies. Novartis' Kisqali approved for broader breast cancer treatment in EU.

NUHCS to start using breakthrough drug for rare lung condition

NUHCS to use sotatercept (Winrevair) for treating pulmonary hypertension, a rare condition affecting 1 in 5,000 Singaporeans. One vial costs $3,700-$6,730 and is given every three weeks. Singapore is the first Asian country to approve the drug, following the US FDA. Early detection is crucial as there is no cure, with lung transplant being the last resort. NUHCS is active in global clinical trials and exploring AI for diagnosis.
© Copyright 2025. All Rights Reserved by MedPath